Cargando…
The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
BACKGROUND: Immune checkpoint inhibitors have been tried for several thoracic malignancies; however, their application as a neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) has not been studied. We evaluated the feasibility and safety of esophagectomy and total lymphadenectomy after...
Autores principales: | Park, Seong Yong, Hong, Min Hee, Kim, Hye Ryun, Lee, Chang Geol, Cho, Jae Ho, Cho, Byoung Chul, Kim, Dae Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711420/ https://www.ncbi.nlm.nih.gov/pubmed/33282345 http://dx.doi.org/10.21037/jtd-20-1088 |
Ejemplares similares
-
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
por: Kim, Yong-Hyub, et al.
Publicado: (2015) -
Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2013) -
Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy
por: Nagaki, Yushi, et al.
Publicado: (2021) -
NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE
por: ALVES, Iuri Pedreira Fillardi, et al.
Publicado: (2021) -
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
por: Shah, Manish A, et al.
Publicado: (2021)